A Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors

Launched by ZHONGNAN HOSPITAL · Mar 13, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Shengxuening Tablets to see how effective it is in treating anemia related to blood cancers, also known as chemotherapy-related anemia. Anemia is a common problem in cancer patients and can make them feel very tired and weak, which affects their quality of life and treatment outcomes. The trial aims to determine if Shengxuening Tablets can help improve blood cell levels and overall health in patients suffering from this condition.

To participate in the study, you need to be over 18 years old and diagnosed with a blood cancer that has caused anemia, with hemoglobin levels between 60 and 100 grams per liter. The study is open to all genders and is currently recruiting participants. If you join, you can expect to take the tablets and be monitored by healthcare professionals to assess how well the treatment works and to ensure your safety. It's important to note that some people may not qualify for the trial due to specific health issues or recent treatments, so discussing your situation with your doctor is essential.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age\>18 years old, gender is not limited;
• • Patients diagnosed with blood cancer complicated with anemia;
• • During the screening period of ≤1 week, hemoglobin (Hb): 60g/L\<Hb≤100g/L;
• • Willingness to treat
• Exclusion Criteria:
• • During the screening period of ≤1 week, hemoglobin (Hb)≤60g/L
• • History of blood transfusion within 1 month;
• • Urgent blood transfusion or EPO infusion is required within the screening period of ≤1 week;
• • Folic acid or vitamin B12 deficiency;
• • History of iron allergy, history of allergy or intolerance to the study drug;
• • Pregnant and lactating women;
• • Age \<18 years old and body weight ≤35kg;
• • Participated in other clinical drug research in the past 3 months;
• • Severe cardiac insufficiency (NYHA grade III or above);
• • Severe abnormal liver function (ALT, AST and TBIL ≥ 2 times the upper limit of normal value);
• • Severe renal insufficiency (creatinine clearance ≤ 15ml/min);
• • Severe mental disorder;
• • Acute and chronic blood loss;
• • Combined with a second tumor;
• • Ferritin\>500μg/L;
• • Combined with active tuberculosis;
• • Failure to cooperate with treatment according to doctor's advice.